BIOTRONIK, INC. INTERPRETATION OF MDR REQUIREMENTS WILL REMAIN UNCHANGED
This article was originally published in The Gray Sheet
Executive Summary
BIOTRONIK, INC. INTERPRETATION OF MDR REQUIREMENTS WILL REMAIN UNCHANGED until FDA clarifies its policy on medical device reporting rules, company Vice President and General Manager Jake Langer says in a July 21 "preliminary response" to a recent warning letter. Biotronik says it believes its current procedures "correctly interpret the MDR regulation" and will change its approach "only upon clear instructions from" FDA's District Office in Bothell, Washington, "a response from Mr. [Bryan] Benesch [from the Division of Surveillance Systems in the device center's Office of Surveillance and Biometrics] to our inquiries, or a change in the MDR regulation."
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.